NASDAQ:RANI Rani Therapeutics (RANI) Stock Price, News & Analysis $2.93 +0.06 (+2.09%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.84▼$3.1050-Day Range$2.85▼$5.5052-Week Range$1.82▼$8.75Volume47,157 shsAverage Volume105,709 shsMarket Capitalization$147.73 millionP/E RatioN/ADividend YieldN/APrice Target$12.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Rani Therapeutics alerts: Email Address Rani Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.14 Rating ScoreUpside/Downside319.3% Upside$12.29 Price TargetShort InterestBearish6.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.05) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.96 out of 5 starsMedical Sector648th out of 936 stocksPharmaceutical Preparations Industry301st out of 436 stocks 3.6 Analyst's Opinion Consensus RatingRani Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRani Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Rani Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.19% of the float of Rani Therapeutics has been sold short.Short Interest Ratio / Days to CoverRani Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Rani Therapeutics has recently decreased by 1.80%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRani Therapeutics does not currently pay a dividend.Dividend GrowthRani Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RANI. Previous Next 1.9 News and Social Media Coverage News SentimentRani Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Rani Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added Rani Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rani Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders53.30% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.19% of the stock of Rani Therapeutics is held by institutions.Read more about Rani Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rani Therapeutics are expected to grow in the coming year, from ($1.05) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rani Therapeutics is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rani Therapeutics is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRani Therapeutics has a P/B Ratio of 5.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rani Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Rani Therapeutics Stock (NASDAQ:RANI)Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Read More RANI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RANI Stock News HeadlinesJuly 23 at 3:36 AM | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Rating of "Buy" by BrokeragesJuly 22, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Astellas Pharma (OtherALPMF) and Verona Pharma (VRNA)July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.July 22, 2024 | msn.comRani Therapeutics prices securities offering to raise $10 millionJuly 22, 2024 | globenewswire.comRani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct OfferingJune 24, 2024 | globenewswire.comRani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity TreatmentMay 14, 2024 | globenewswire.comRani Therapeutics to Participate in May Investor ConferencesMay 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.May 9, 2024 | msn.comRANI: 1Q:24 ResultsMay 9, 2024 | globenewswire.comRani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024May 8, 2024 | markets.businessinsider.comEdward Nash Maintains Buy Rating on Rani Therapeutics Amid Strong Financials and Promising Clinical TrialsMay 7, 2024 | finance.yahoo.comRani Therapeutics Q1 2024 Earnings: Financial Performance and Strategic UpdatesMay 6, 2024 | investorplace.comRANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q1 2024May 6, 2024 | globenewswire.comRani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate UpdateMay 2, 2024 | finance.yahoo.comFavourable Signals For Rani Therapeutics Holdings: Numerous Insiders Acquired StockApril 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)April 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)See More Headlines Receive RANI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RANI CUSIPN/A CIK1856725 Webwww.ranitherapeutics.com Phone408-457-3700FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price Target$12.29 High Stock Price Target$17.00 Low Stock Price Target$8.00 Potential Upside/Downside+315.1%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.61% Return on Assets-49.87% Debt Debt-to-Equity Ratio1.43 Current Ratio3.09 Quick Ratio3.09 Sales & Book Value Annual Sales$2.72 million Price / Sales54.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book5.80Miscellaneous Outstanding Shares50,420,000Free Float23,546,000Market Cap$149.24 million OptionableOptionable Beta0.16 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Mir A. Imran (Age 67)Executive Chairman Comp: $80kMr. Talat Imran (Age 42)CEO & Director Comp: $450kMr. Svai S. Sanford (Age 54)Chief Financial Officer Comp: $416kDr. Mir Hashim (Age 64)Chief Scientific Officer Comp: $416kMr. Eric Groen (Age 53)General Counsel Ms. Bella VazquezVice President of Human ResourcesMs. Kate McKinley M.B.A. (Age 47)Chief Business Officer Ms. Arvinder DhallaVice President of Clinical DevelopmentMore ExecutivesKey CompetitorsChiasmaNASDAQ:CHMAPassage BioNASDAQ:PASGApollo EndosurgeryNASDAQ:APENPharming GroupNASDAQ:PHARLarimar TherapeuticsNASDAQ:LRMRView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 16,956 shares on 5/10/2024Ownership: 1.366%Talat ImranBought 10,000 shares on 12/6/2023Total: $22,700.00 ($2.27/share)Talat ImranBought 5,000 shares on 12/4/2023Total: $12,850.00 ($2.57/share)Talat ImranBought 20,000 shares on 11/29/2023Total: $41,000.00 ($2.05/share)Cortes Isidoro Alfonso QuirogaSold 5,265,165 sharesTotal: $10.58 M ($2.01/share)View All Insider TransactionsView All Institutional Transactions RANI Stock Analysis - Frequently Asked Questions How have RANI shares performed this year? Rani Therapeutics' stock was trading at $3.32 at the beginning of 2024. Since then, RANI stock has decreased by 11.7% and is now trading at $2.93. View the best growth stocks for 2024 here. How were Rani Therapeutics' earnings last quarter? Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) announced its quarterly earnings data on Monday, May, 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.06. When did Rani Therapeutics IPO? Rani Therapeutics (RANI) raised $100 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share. How do I buy shares of Rani Therapeutics? Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RANI) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
